The review investigated the effect of aspirin combined with warfarin in patients recovering from acute coronary syndromes. The review concluded that at an international normalised ratio of 2-3 the combination of aspirin and warfarin is superior to aspirin alone in reducing the risk of major adverse events, although it significantly increases the risk of major bleeding. The conclusion appears reliable.
Data extraction
Three independent reviewers extracted the data and any disagreements were resolved by consensus. Odds ratios (ORs) for single and composite MAEs and MB were calculated.
Methods of synthesis
How were the studies combined? Both fixed-effect and random-effects models were used to calculate the summary ORs with 95% confidence intervals (CIs) for binary outcomes. The number-needed-to-treat (NNT) to prevent one MAE and the number-needed-to-harm (NNH) by causing one MB were also calculated. Publication bias was assessed using a funnel plot and Egger's test.
How were differences between studies investigated?
Heterogeneity amongst the studies was assessed using the Cochran Q statistic and the I-squared measure. A sensitivity analysis was used to assess the contribution of each study to the pooled estimates by excluding trials one at a time, starting from those with the lowest quality score. The statistical analyses were performed for all studies and also for studies with target or measured INRs of between 2 and 3.
Results of the review
Fourteen RCTs (n=25,307) were included.
The authors stated that, because there was no significant difference between the results of the random-effects and fixedeffect models, they only reported the results of the fixed-effect model.
All studies included in the analysis, irrespective of the INR.
The combination of A+W had no significant effect on the risk of an MAE (OR 0.96, 95% CI: 0.90, 1.03, P=0.30), but increased the risk of MB (OR 1.77, 95% CI: 1.47, 2.13, P<0.00001; NNH 100). It was also associated with an increased risk of extracranial bleeding (OR 2.2, 95% CI: 1.64, 2.96, P<0.00001) but had no significant effect on intracranial bleeding (OR 1.37, 95% CI: 0.79, 2.37, P=0.27).
Combination therapy had no significant effect on all-cause death or nonfatal MI, although it significantly reduced the risk of nonfatal thromboembolic stroke (OR 0.81, 95% CI: 0.67, 0.97, P=0.02; NNT 100).
Analyses restricted to studies with INRs of between 2 and 3.
The combination of A+W significantly reduced the risk of an MAE (OR 0.73, 95% CI: 0.63, 0.84, P<0.0001; NNT 33), but increased the risk of MB (OR 2.32, 95% CI: 1.63, 3.29, P<0.00001; NNH 100). It was also associated with an increased risk of extracranial bleeding (OR 2.37, 95% CI: 1.37, 4.10, P=0.002) but had no statistically significant effect on intracranial bleeding (OR 3.02, 95% CI: 0.61, 15.02, P=0.18).
Combination therapy had no significant effect on all-cause death, but it was associated with a 57% reduction in the risk of nonfatal thromboembolic stroke (OR 0.43, 95% CI: 0.27, 0.70, P=0.0007; NNT 100) and a 30% reduction in the risk of nonfatal MI (OR 0.70, 95% CI: 0.52, 0.95, P=0.0003; NNT 50).
Thirteen of the 14 studies were of a good quality and had greater than 97% follow-up. No study was excluded because of a follow-up of less than 80%. In the sensitivity analysis, the exclusion of any trial did not significantly alter the overall results. Significant heterogeneity was found when data were pooled for MAEs irrespective of INR (P=0.001), but when the analysis was restricted to the studies with an INR of 2-3 there was no significant heterogeneity.
The funnel plot suggested the possibility of publication bias. However, Egger's test showed no publication bias for studies with an INR of 2-3 (P=0.141 for all studies and P=0.646 for studies with an INR of 2-3).
